FINWIRES · TerminalLIVE
FINWIRES
$ABBV

$ABBV

76 stories mentioning ABBVUpdated 3d ago

Every FINWIRES story that references ABBV, newest first.

What are analysts saying about ABBV?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on ABBV?

Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index rising 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.8%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In corporate news, AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9 billion, as the drugmaker looks to boost its immunology portfolio and accelerate its clinical presence in the respiratory segment. AbbVie shares jumped past 6%, and Apogee surged 46%.Regenxbio (RGNX) shares jumped 18% after it said the US Food and Drug Administration has agreed on the next steps for a potential accelerated approval of Navsunli, its experimental gene therapy for Mucopolysaccharidosis II, following discussions related to its appeal of a complete response letter issued in February.Jaguar Health (JAGX) shares climbed 16% after the firm said Monday its board has started a process to explore strategic alternatives to maximize shareholder value.Vivos Therapeutics (VVOS) shares fell 14% after it said Monday it has extended its strategic financing agreement with Streeterville Capital through Aug. 31, giving it additional time to complete planned capital-raising efforts.

$ABBV$APGE$JAGX$RGNX$VVOS
Update: Equities Mixed Intraday, Oil Falls as US-Iran Talks Advance
US Markets

Update: Equities Mixed Intraday, Oil Falls as US-Iran Talks Advance

(Updates with latest market prices and developments.)US benchmark equity indexes were mixed intraday, while oil prices fell as markets reacted to progress in fresh talks between Washington and Iran.The Nasdaq Composite was down 1.2% at 26,209.5 after midday Monday, while the S&P 500 fell 0.3% to 7,477.4. The Dow Jones Industrial Average rose 0.4% to 51,762. Among sectors, communication services saw the biggest drop, while real estate paced the gainers.US markets were closed Friday for the Juneteenth National Independence Day holiday.Brent crude oil was down 3.6% at $77.71 a barrel intraday Monday, while West Texas Intermediate fell 2.3% to $73.60.Iran has agreed to admit inspectors from the International Atomic Energy Agency in the country, news outlets reported, citing US Vice President JD Vance."That is a major milestone for the American people, and the first step in permanently denuclearizing or permanently ending a nuclear weapons program in Iran, and that's exactly what we wanted to do," Vance reportedly said."Everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure 'nuclear honesty' long into the future," US President Donald Trump said in a social media post Monday.On the status of the Strait of Hormuz, Vance said the crucial waterway is open, and negotiations with Iran are focused on setting up a "coordination mechanism" for demining and resuming trade, CNN reported.Earlier, Trump threatened further strikes on Iran, if Hezbollah in Lebanon continued attacking Israel."Recent developments show that moving towards a more permanent deal will be challenging, with very real risks of a flare-up in hostilities during the 60-day ceasefire," ING Bank said in a report. "For energy markets, the key factor is still whether oil and LNG flows from the Persian Gulf continue to recover, despite all the rhetoric."US Treasury yields were higher intraday, with the 10-year rate up 5.4 basis points at 4.51% and the two-year rate rising 4.7 basis points to 4.23%.In company news, Space Exploration Technologies (SPCX) agreed to grant Reflection AI access to the rocket and satellite company's computing infrastructure for up to $6.3 billion, CNBC reported.Separately, SpaceX said it launched its first offering of senior unsecured notes to repay outstanding bridge loan debt and cover general corporate expenses.SpaceX shares were down 9.9% intraday.Lucid Group (LCID) outlined plans to cut 18% of its total workforce, including removing the chief operations role, as part of a plan to streamline its structure and boost profitability. The electric vehicle manufacturer's shares were down 4.5%.AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9 billion, as the drugmaker looks to strengthen its immunology portfolio and accelerate its clinical presence in the respiratory segment.AbbVie shares were up 7%, among the top performers on the S&P 500, while Apogee surged 47%.Gold was down 1.2% at $4,195.80 per troy ounce, while silver decreased 1.4% to $65.91 per ounce.

Dow JonesNasdaq CompositeS&P 500$ABBV$APGE$LCID$SPCX
Wire

Top Midday Gainers

Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engagement with Boltz, an AI research lab, to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier proteins of interest to MitoCareX's pipeline.Shares jumped over 200% as trading volume catapulted to over 55 million from a daily average of about 208,000.AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion, the companies said Monday.Shares of Apogee soared 47%, with intraday trading volume of over 47.1 million against a daily average of about 975,000.Definium Therapeutics (DFTX) reported positive topline results from a phase 3 Emerge study of DT120 orally disintegrating tablet in major depressive disorder.RBC Capital raised its price target to $57 from $36, while maintaining its outperform rating.Shares surged 52% amid a jump in intraday trading volume to over 16 million from a daily average of roughly 1.9 million.Price: $15.55, Change: $+10.47, Percent Change: +206.08%

$ABBV$APGE$DFTX$NXTS
Asia Markets

Update: US Equity Indexes Mixed Amid Steep Decline in Communication Services, Surging Treasury Yields

(Updates with index/price moves and political/company news from the first paragraph.)US equity indexes traded mixed amid steep declines in communication services and consumer discretionary and rising government bond yields after midday Monday.The Nasdaq Composite dropped 1.2% to 26,194.83, with the S&P 500 down 0.4% to 7,472, while the Dow Jones Industrial Average rose 0.3% to 51,696.7.All sectors, except communication services, consumer discretionary, consumer staples and technology, gained. Real estate and healthcare led the gainers. Communication services sank 4.4%, and consumer discretionary was down 2%.Alphabet (GOOG, GOOGL) Google DeepMind data scientist and Nobel Prize winner John Jumper is leaving to join Amazon (AMZN) and Alphabet-backed Anthropic, he said Friday. Shares of Alphabet slumped nearly 6%, one of the steepest decliners on the S&P 500 and the Nasdaq.Netflix (NFLX) is looking to pursue additional partnerships with traditional broadcasters following the launch of its agreement with French broadcaster TF1, Chief Executive Officer Greg Peters told the Financial Times on Friday. Shares of Netflix dropped 6%, among the worst performers on the Nasdaq and the S&P 500.In geopolitical news, US Vice President JD Vance said Monday that Iran agreed to allow International Atomic Energy Agency inspectors into the country, according to media reports. "That is a major milestone for the American people, and the first step in permanently denuclearizing or permanently ending a nuclear weapons program in Iran, and that's exactly what we wanted to do," Vance was cited as saying.Iran's Foreign Minister Araghchi and the country's top negotiator Mohammad Bagher Ghalibaf are traveling to Oman to discuss the management of the Strait of Hormuz, Al Jazeera reported on Monday. The two are set to discuss consolidating Iranian arrangements for managing the strait and enhancing bilateral coordination, Ghalibaf said on Telegram, according to the news report.Front-month global benchmark North Sea Brent slumped 3.4% to $77.87 per barrel. The US West Texas Intermediate dropped 3% to $73.66 per barrel.Most US Treasury yields jumped, with the 10-year up six basis points to 4.52%. The two-year rate jumped 4.9 basis points to 4.23%. Even as oil prices have been declining since an interim peace deal was signed between the US and Iran, the market is still pricing two interest rate increases -- 25 basis points each -- by the end of this year, according to the CME FedWatch tool, following the hawkish lean seen in the June monetary policy announcement last week.In precious metals, gold futures fell 0.9% to $4,209.1, while silver futures declined 1% to $65.68.In company news, Chevron (CVX) has agreed to build a power plant in West Texas to supply electricity to a data center operated by technology giant Microsoft (MSFT), as part of a 20-year power purchase deal. Shares of Microsoft dropped 2.5%, among the steepest decliners on the Dow.AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal of about $10.9 billion, as the drugmaker looks to strengthen its immunology portfolio and accelerate its clinical presence in the respiratory segment. Shares of AbbVie advanced nearly 7%, one of the top gainers on the S&P 500.CRH (CRH) said it agreed to acquire building materials rival Arcosa (ACA) in an all-cash transaction valued at about $8.5 billion, expanding its infrastructure products business and strengthening its position in North America.

Dow JonesNasdaq CompositeS&P 500$ABBV$ACA$AMZN$APGE$CRH$CVX$GOOG$GOOGL$MSFT$NFLX
Sectors

Sector Update: Healthcare Stocks Rise Monday Afternoon

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index rising 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9 billion, as the drugmaker looks to boost its immunology portfolio and accelerate its clinical presence in the respiratory segment. AbbVie shares jumped past 7%, and Apogee surged 46%.Jaguar Health (JAGX) shares climbed up past 9% after the firm said Monday its board has started a process to explore strategic alternatives to maximize shareholder value.Definium Therapeutics (DFTX) shares soared 55% after the firm said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, and all key secondary endpoints.

$ABBV$DFTX$JAGX
Sectors

Sector Update: Healthcare

Healthcare stocks were higher Monday afternoon, with the NYSE Healthcare Index rising 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.2%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In corporate news, AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9 billion, as the drugmaker looks to strengthen its immunology portfolio and accelerate its clinical presence in the respiratory segment. AbbVie shares jumped 7%, and Apogee surged 46%.

$ABBV$APGE
Wire

Top Midday Stories: Treasury Authorizes Sale of Iranian Oil; SpaceX launches First Inaugural Bond Issuance

The Nasdaq Composite and S&P 500 were down, while the Dow Jones Industrial Average was up in late-morning trading Monday, as market participants assess the latest developments in negotiations between the US and Iran.The US Department of the Treasury on Monday said it has issued a general license authorizing the production, delivery, and sale of crude oil, petrochemical products and petroleum products of Iranian origin through Aug. 21.In company news, SpaceX (SPCX) has commenced its first offering of senior unsecured notes, the proceeds of which will be used to repay outstanding borrowings under its bridge loan facility and to pay related fees and expenses, the company said Monday in a regulatory filing. The remainder of the proceeds will go toward general corporate purposes, the filing said. Separately, SpaceX has signed a roughly $6.3 billion computing power agreement with Reflection AI, CNBC reported, citing materials it viewed. Under the deal, Reflection will get access to Nvidia (NVDA) GB300s and will pay SpaceX $150 million per month from July 1 through 2029, the report said. SpaceX shares were down 8.7% around midday, while Nvidia eased 0.3%.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion, the companies said Monday. The acquisition includes Apogee's pipeline of multiple clinical-stage drug candidates for inflammatory and immunological diseases, they said. The deal is expected to close in Q3. AbbVie shares were up 5.9%, while Apogee shares were up 46.8%.Chevron (CVX) said Monday its Energy Forge One subsidiary has signed a 20-year power purchase agreement with Microsoft (MSFT) for a planned data center in West Texas to be operated by the tech giant. The data center, known as Project Kilby, is expected to eventually deliver about 2.67 gigawatts of capacity. Chevron shares were up 0.2%, while Microsoft was down 2.1%.Getty Images (GETY) said Sunday it has entered into a display agreement with OpenAI under which Getty content will be displayed within ChatGPT. Getty shares were up 110%.Meta Platforms (META) is investing $900 million in Cred, an Indian fintech startup, and it plans to appoint its founder, Kunal Shah, as the new leader of WhatsApp, Bloomberg reported Monday, citing a news release. Following the investment, Meta will own roughly 20% of Cred, which will be valued at $4.5 billion post-money, the report said. Meta shares were down 2.7%.Morgan Stanley (MS) has identified two sites within the city of Dallas for a phased approach to establishing a new large-scale operations hub, according to a city document. In the first phase, Morgan Stanley would invest about $96.9 million in real estate and business personal property improvements as part of a roughly 52-month lease of office space at a temporary location. For phase two, Morgan Stanley would invest about $684.2 million in real estate and business personal property improvements at a permanent location by the end of 2031. An additional estimated $650 million would then be expended by the developer/landlord to deliver the core and shell building at the permanent location, the document said. Morgan Stanley shares were up 1.7%.Price: $169.37, Change: $-15.64, Percent Change: -8.45%

$ABBV$APGE$CVX$GETY$META$MS$MSFT$NVDA$SPCX
AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal
US Markets

AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Deal

AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) in an all-cash deal worth about $10.9 billion, as the drugmaker looks to strengthen its immunology portfolio and accelerate its clinical presence in the respiratory segment.AbbVie will pay $135.11 a share in cash for Apogee, the companies said in a joint statement Monday. Apogee's shares surged by about 47% in Monday trading, while AbbVie gained 3.7%.The transaction will give AbbVie access to Apogee's portfolio of clinical-stage candidates currently in development for the treatment of inflammatory and immunological diseases, including atopic dermatitis and asthma.The company's lead candidate, zumilokibart, for atopic dermatitis showed "clinically significant results" in a phase 2 trial. Apogee is also developing APG273, a combination of zumilokibart with the thymic stromal lymphopoietin-blocking antibody APG333, for patients with asthma."The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders," AbbVie Chief Executive Robert Michael said in a statement. "Apogee's pipeline adds highly differentiated clinical-stage assets, further expanding our robust immunology portfolio."The deal, which requires approval from regulators and clearance from Apogee's shareholders, is expected to close in the third quarter. AbbVie said the acquisition will be accretive to its adjusted earnings per share starting in 2032."This transaction reflects the strength of Apogee's vision, our team's dedication and the significant progress we've made advancing zumilokibart and our differentiated pipeline," Apogee CEO Michael Henderson said. "This transaction delivers substantial shareholder value and positions our programs to reach their full potential."In May, Apogee reported a first-quarter net loss of $74.1 million, compared with a loss of $55.3 million a year earlier. In the same month, the company announced a strategic financing collaboration with Blackstone (BX) Life Sciences for up to $1.3 billion to support the clinical development and potential commercialization of zumilokibart.AbbVie raised its full-year outlook in April as the biopharmaceutical company recorded better-than-expected first-quarter results.

$ABBV$APGE
Sectors

Sector Update: Healthcare Stocks Flat to Lower Premarket Monday

Healthcare stocks were flat to lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.3%.Definium Therapeutics (DFTX) shares were up more than 60% after the company said the phase 3 Emerge trial of a single 100-microgram dose of DT120 orally disintegrating tablet in major depressive disorder met the primary endpoint, along with all key secondary efficacy endpoints.MapLight Therapeutics' (MPLT) phase 2 trial of ML-004 in autism spectrum disorder failed to meet its primary endpoint in social communication, the company said. MapLight Therapeutics stock was up 1.6% premarket.

$ABBV$APGE$DFTX$IBB$MPLT$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were steady premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) inactive.AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion. Shares of Apogee Therapeutics were up nearly 47% pre-bell, while AbbVie rose 2.4%.

$ABBV$APGE
Commodities

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Amid Continued US-Iran Talks

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively traded Invesco QQQ Trust (QQQ) advanced 0.2% in Monday's premarket activity, as traders focused on continuing US-Iran talks for a potentially positive outcome.US stock futures were higher, with S&P 500 Index futures up 0.1%, Dow Jones Industrial Average up 0.01%, and Nasdaq futures gaining 0.3% before the start of regular trading.Federal Reserve Governor Christopher Waller is slated to speak on Monday.In premarket action, bitcoin was up by 0.7%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 2.6% higher, Ether ETF (EETH) advanced 2.4%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 0.02%.Power Play:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) retreated by 0.1%, the Vanguard Health Care Index Fund (VHT) was up 0.2%, while the iShares US Healthcare ETF (IYH) advanced by 0.03%. The iShares Biotechnology ETF (IBB) was 0.8% higher.Apogee Therapeutics (APGE) stock rose more than 47% premarket after AbbVie (ABBV) agreed to acquire Apogee for $135.11 per share in cash for a total equity value of $10.9 billion. AbbVie shares were 1.1% higher.Winners and Losers:IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) advanced 0.2%, while the Vanguard Industrials Index Fund (VIS) retreated 0.7% and the iShares US Industrials ETF (IYJ) was 0.5% lower.SpaceX (SPCX) stock was down by nearly 4% before the opening bell following a 3.6% fall at the prior close. The Financial Times reported Sunday that the company was assigned MSCI's lowest possible ESG rating, triple-C, just ahead of its $75 billion initial public offering earlier this month.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was down 0.7%, the Vanguard Consumer Staples Index Fund ETF Shares (VDC) retreated 0.1%, and the iShares US Consumer Staples ETF (IYK) was inactive. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.4%. The VanEck Retail ETF (RTH) was inactive, while the State Street SPDR S&P Retail ETF (XRT) was flat.Maplebear (CART) shares were down 2% pre-bell after closing Friday with a 4% rise. The company said Monday it launched a short-form vertical video feature that allows users to browse and shop meal and recipe content within retailer storefronts on its platform.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated 0.2%. Direxion Daily Financial Bull 3X Shares (FAS) was up 0.4%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.4% lower.Robinhood Markets (HOOD) shares traded down 2% in early hours activity after the company said it plans to offer $2 billion worth of convertible senior notes due 2029 in a private placement.TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.4%, and the iShares US Technology ETF (IYW) was 0.1% higher, while the iShares Expanded Tech Sector ETF (IGM) was down 1.6%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) was up 2.2%, while the iShares Semiconductor ETF (SOXX) rose by 1.3%.ServiceNow (NOW) shares were down more than 1% in premarket activity. The company said it has teamed up with Inspira Enterprise to offer the full suite of ServiceNow capabilities to enterprises worldwide through the IT services and consulting firm's platform.EnergyThe iShares US Energy ETF (IYE) was flat, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 0.1%.CMB.TECH (CMBT) stock was up more than 2% before market open after the company said it will charter up to 12 shipping vessels capable of being powered by ammonia to Fortescue, an Australian metals and green-energy enterprise.CommoditiesFront-month US West Texas Intermediate crude oil retreated by 0.9% to $75.17 per barrel on the New York Mercantile Exchange. Natural gas gained by 2.2% to $3.31 per 1 million British Thermal Units. The United States Oil Fund (USO) declined by 1.6%, while the United States Natural Gas Fund (UNG) was 2% higher.Gold futures for July were down by 0.5% to $4,223.20 an ounce on the Comex. Silver futures advanced by 0.1% to $66.84 an ounce. SPDR Gold Shares (GLD) declined by 0.2%, and the iShares Silver Trust (SLV) was 1.1% higher.

Dow JonesNasdaq CompositeS&P 500$ABBV$APGE$BETH$BITO$CART$CMBT$EEM$EETH$EXI$FAS$FAZ$GLD$HOOD$IBB$IGM$IGV$IPK$IVV$IWM$IYE$IYH$IYJ$IYK$IYW$NOW$PMR$QQQ$RTH$SLV$SOXX$SPCX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Asia Markets

Update: US Equity Futures Slightly Higher Pre-Bell As US-Iran Talks Start in Switzerland

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were marginally higher pre-bell Monday as traders considered the latest developments in the initial talks between the US and Iran, which target a more permanent peace deal.Dow Jones Industrial Average futures were 0.2% higher, S&P 500 futures were flat, and Nasdaq futures were 0.3% higher.After a memorandum of agreement was signed last week between US and Iran, US Vice President JD Vance and Iran's parliamentary speaker Mohammad Bagher Qalibaf completed the first round of high-level talks in Switzerland aimed at ending the war in the Middle East. Mediators Pakistan and Qatar said there was "encouraging progress" made in the negotiations, with technical discussions continuing this week.However, shipping stalled in the Strait of Hormuz over the weekend after Iran declared the waterway closed once again due to Israeli strikes in Lebanon, CNBC reported, citing data from maritime intelligence firm Windward. President Donald Trump said in a post on Truth Social that Iran should stop its proxies in Lebanon "from causing trouble." Trump added, "If they don't, we'll hit Iran very hard again, just like we did last week, only harder!!!"FedEx (FDX) and Micron Technology (MU), among others, are scheduled to report quarterly financial results this week.Oil prices were lower, with front-month global benchmark North Sea Brent crude down 2.5% at $78.06 per barrel and US West Texas Intermediate crude 1.7% lower at $74.56 per barrel.The economic calendar is vacant on Monday.In other world markets, Japan's Nikkei closed 1.6% higher, Hong Kong's Hang Seng ended 0.7% lower, and China's Shanghai Composite finished 1.8% higher. Meanwhile, the UK's FTSE 100 was up 0.5%, and Germany's DAX index was flat in Europe's early afternoon session.In equities, Alphabet (GOOG, GOOGL) shares were down 2.1% after Google DeepMind data scientist and Nobel Prize winner John Jumper said he is leaving the company to join Anthropic. SpaceX (SPCX) stock was down 3.8% after a Financial Times report that the company was assigned MSCI's lowest possible ESG rating, triple-C, ahead of its $75 billion initial public offering earlier this month. Robinhood Markets (HOOD) stocks fell 1.3% after the company said it plans to offer $2 billion worth of convertible senior notes due 2029 in a private placement.On the winning side, AbbVie (ABBV) and Apogee Therapeutics (APGE) shares were up 1.1% and 47%, respectively, after the two companies said AbbVie has agreed to acquire Apogee Therapeutics for $135.11 per share in cash for a total equity value of $10.9 billion.

Dow JonesNasdaq CompositeS&P 500$ABBV$APGE$FDX$GOOG$GOOGL$HOOD$MU$SPCX
Wire

CMS Proposes Permanent Framework for Medicare Drug Price Negotiation Program

The Centers for Medicare & Medicaid Services on Friday proposed a rule to establish a permanent regulatory framework for the Medicare Drug Price Negotiation Program beginning with the 2029 price applicability year, transitioning from implementation through annual guidance to codified regulations.The proposal would govern future negotiations and renegotiations for high-cost, single-source drugs covered under Medicare Part D and Part B. CMS said it will select up to 20 additional negotiation-eligible drugs for the fourth cycle of negotiations and future cycles of the program.The rule also proposes a temporary pricing floor for certain small biotech drugs in 2029 and 2030.CMS said it has negotiated prices for 25 high-expenditure drugs during the program's first two years. Maximum fair prices for the first 10 selected drugs took effect Jan. 1, 2026.Price: $236.56, Change: $-4.31, Percent Change: -1.79%

$ABBV$JNJ$LLY$MRK$NVO
Wire

Morgan Stanley Adjusts Price Target on AbbVie to $278 From $270

AbbVie (ABBV) has an average rating of overweight and mean price target of $253.15, according to analysts polled by FactSet.Price: $213.21, Change: $+9.32, Percent Change: +4.57%

$ABBV
Wire

Goldman Sachs Adjusts AbbVie Price Target to $244 From $240

AbbVie (ABBV) has an average rating of overweight and mean price target of $253.15, according to analysts polled by FactSet.Price: $212.19, Change: $+8.30, Percent Change: +4.07%

$ABBV
Wire

AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says

AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competition eroding its business are "overdone," BofA Securities said in a note Thursday.The brokerage said the growth outlook for the company's Skyrizi medication remains solid, with no evidence of slowing demand across psoriasis or inflammatory bowel disease. Johnson & Johnson's (JNJ) IL-23 products appear to be category expanding rather than taking market share from AbbVie, according to the note.During its earnings call, AbbVie stated that Skyrizi's intellectual property extend into the mid-2030s and beyond, which the brokerage believes is a potential upside given the company's history of successfully defending drug patents.Compared with its large-cap pharmaceutical peers, AbbVie is projected to grow revenue at about 6% per year over 5 and 7 years, versus a peer average of 3% to 4%, BofA said. At its current reasonable valuation, the company offers "one of the best" growth profiles in the industry, with room for upside on the success of its early and mid-pipeline efforts, the brokerage said.BofA upgraded AbbVie to buy from neutral, and raised the price target to $234 from $226.Shares of AbbVie were up more than 4% in Thursday trading.Price: $212.77, Change: $+8.88, Percent Change: +4.36%

$ABBV$JNJ
Research

BofA Securities Upgrades AbbVie to Buy From Neutral

AbbVie (ABBV) has an average rating of overweight and mean price target of $253.15, according to analysts polled by FactSet.

$ABBV
Sectors

Sector Update: Health Care Stocks Fall Late Afternoon

Health care stocks declined late Wednesday afternoon, with the NYSE Health Care Index down 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Boston Scientific (BSX) shares fell 3.3% after Daiwa Securities downgraded the stock to neutral from outperform, and lowered its price target to $60 per share from $83 earlier.AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.7%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.1%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged 38%.

$ABBV$AZN$BSX$KALV
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) fell 2%.In corporate news, AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.4%.AstraZeneca (AZN) will invest 300 million pounds ($404.9 million) in the UK, focusing on its sites in Cambridge and Macclesfield, in a move aimed at boosting the country's life sciences sector, Bloomberg reported. AstraZeneca shares were down 1.2%.KalVista Pharmaceuticals (KALV) and Chiesi Group said Wednesday they have signed an agreement through which Chiesi will buy KalVista for $27 per share in cash, or about $1.9 billion. KalVista shares surged nearly 39%.

$ABBV$AZN$KALV
Sectors

Sector Update: Health Care

Health care stocks declined Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) fell 1.7%.In corporate news, AbbVie (ABBV) raised its full-year outlook on Wednesday as the biopharmaceutical company recorded better-than-expected Q1 results, driven by robust revenue growth from its Skyrizi and Rinvoq immunology drugs. Its shares rose 3.3%.

$ABBV

Showing 41-60 of 76

Track with the FINWIRES app suite